Search results

The final report on the safety of Building 23 by the independent expert review team has been completed.

See details of previously published customer updates from our Health products team. 

ANSTO is seeking nominations for the ANSTO Australian Synchrotron Stephen Wilkins Thesis Medal.

The nuclear medicine community has welcomed the Australian Government’s decision to provide $30 million in funding to ANSTO for the design of a new nuclear medicine manufacturing facility.

Science and medical experts meet in Adelaide to discuss great potential of particle therapy in Australia

ANSTO has been tracking and publishing data on fine particle pollution from key sites around Australia, and internationally, for more than 20 years.  

Read about an ANSTO scientist and their work to prepare for a school project or interview.

Professor Peter Lay from the University of Sydney has been awarded the Australian Synchrotron Lifetime Contribution Award by ANSTO, the Australian Nuclear Science and Technology Organisation.

By submitting a proposal for Merit Access to ANSTO’s Biosciences, Centre for Accelerator Science, Isotope Tracing, Nuclear Stewardship or the Vivarium capabilities, you are agreeing to the following Terms and Conditions. These Terms and Conditions apply to external merit researchers, scientific collaborators and partners unless there is a specific agreement in place between ANSTO and the home institution of the Principal Investigator.

Cyclotek and ANSTO have announced the launch of a Joint Venture (JV), to establish Australia’s first GMP (Good Manufacturing Practice) theranostics facility starting in Melbourne, Australia.

Technical information on the Far Infrared beamline at the Australian Synchrotron.

Researchers and industry partners from UNSW Australia, the Australian Centre for Nanomedicine, Children’s Cancer Institute and Inventia Life Sciences Pty Ltd have been awarded the 2021 ANSTO Eureka Prize for Innovative Use of Technology for their method to rapidly-produce 3D cell structures

In 2017, ANSTO's CEO signed a Memorandum of Understanding with Sri Lanka to work together to investigate the epidemiology of Chronic Kidney Disease of unknown origin (CKDu).

The protein mapping workhorses of the Australian Synchrotron, Macromolecular and Microfocus crystallography beamlines, MX1 and 2, continue to support important biomedical research in the development of vaccines and new therapeutics.